Roivant Sciences Ltd.
ROIV
$11.40
$0.3152.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -16.06% | 101.52% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -16.06% | 101.52% | |||
| Cost of Revenue | 3.49% | -0.89% | |||
| Gross Profit | -4.83% | 4.23% | |||
| SG&A Expenses | 72.04% | 12.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 36.78% | 5.38% | |||
| Operating Income | -38.59% | -3.69% | |||
| Income Before Tax | 13.41% | -4.51% | |||
| Income Tax Expenses | 292.90% | -305.23% | |||
| Earnings from Continuing Operations | -20.79% | 11.78% | |||
| Earnings from Discontinued Operations | -100.00% | 859.05% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -10.54% | 3.15% | |||
| Net Income | -221.90% | 173.59% | |||
| EBIT | -38.59% | -3.69% | |||
| EBITDA | -36.50% | -3.73% | |||
| EPS Basic | -224.53% | 174.89% | |||
| Normalized Basic EPS | -91.83% | -15.94% | |||
| EPS Diluted | -226.28% | 174.28% | |||
| Normalized Diluted EPS | -91.83% | -15.94% | |||
| Average Basic Shares Outstanding | -2.13% | -1.73% | |||
| Average Diluted Shares Outstanding | -2.13% | -1.73% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||